YahooOctober 13, 2026 at 7:00 AM NY14 Days Ago
Regeneron reports 84-week Phase III data for Pasatru in adult FOP
The trial showed that Pasatru prevented new heterotopic ossification lesions, compared to nine in the placebo cohort.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
